Effect of daily consumption of probiotic yogurt in patients with non-alcoholic fatty liver

Not Applicable

Conditions: on-alcoholic fatty liver disease.
Fatty (change of) liver, not elsewhere classified
K76.0

Registration Number: IRCT20210201050210N1

Lead Sponsor: Tehran University of Medical Sciences

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Pending

Sex: All

Target Recruitment: 68

Inclusion Criteria

Non-alcoholic fatty liver disease was approved by a gastroenterologist using fibroscan examination
Individuals aged 20 to 60 years
Patients have a fixed plan for medication use during the last 3 months
Body mass index between 25 to 35 kg/m 2

Exclusion Criteria

Smokers
History of alcohol consumption
Adherence to a special diet in the last 3 months
Pregnant or lactating women or those planning to get pregnant in the next three months
Menopausal women
Individuals with pathologic conditions affecting the liver, including acute and chronic hepatitis, viral hepatitis, liver transplantation, autonomic hepatitis, hemochromatosis, primary biliary cirrhosis, Wilson's disease, antitrypsin deficiency and thyroid disease
People with lactose intolerance
People taking antibiotics
patients taking medications affecting serum lipids
Individuals taking multivitamin-minerals during the previous month
Patients who have used any type of probiotic product in the last two months

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Hepatic steatosis. Timepoint: Beginning the intervention and 12 weeks later at the end of the intervention. Method of measurement: Fibro-scan.;Hepatic fibrosis. Timepoint: Beginning the intervention and 12 weeks later at the end of the intervention. Method of measurement: Fibro-scan.;Liver enzyme (ALT, AST and GGT). Timepoint: Beginning the intervention and 12 weeks later at the end of the intervention. Method of measurement: Blood sample.

Secondary Outcome Measures

Name	Time	Method
ipid profile (TG, Total cholesterol, LDL-c and LDH-c). Timepoint: Beginning the intervention and 12 weeks later at the end of the intervention. Method of measurement: Blood sample.;Glycemic index (FBS, FBI, HOMA-IR and QUICKI). Timepoint: Beginning the intervention and 12 weeks later at the end of the intervention. Method of measurement: Blood sample.;Weight. Timepoint: Beginning the intervention and 12 weeks later at the end of the intervention. Method of measurement: Scales.;Waist circumference. Timepoint: Beginning the intervention and 12 weeks later at the end of the intervention. Method of measurement: Tape meter.;Body mass index (BMI). Timepoint: Beginning the intervention and 12 weeks later at the end of the intervention. Method of measurement: Formula (weight (kilograms) divided by the squared height (meters)).